Skye Bioscience, Inc. (SKYE) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
SKYE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SKYE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export SKYE earnings history in CSV or JSON format
Free sign-in required to download data
Skye Bioscience, Inc. (SKYE) Earnings Overview
As of May 8, 2026, Skye Bioscience, Inc. (SKYE) reported trailing twelve-month net income of -$56M, reflecting -93.2% year-over-year growth. The company earned $-1.41 per diluted share over the past four quarters.
Looking at the long-term picture, SKYE's historical earnings data spans multiple years. The company achieved its highest annual net income of $1M in fiscal 2019.
Skye Bioscience, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATAI (-$154M net income, -48464.0% margin), CMPS (-$288M net income), MNMD (-$238M net income), SKYE has comparable earnings metrics. Compare SKYE vs ATAI →
SKYE Earnings vs Peers
Earnings metrics vs comparable public companies
SKYE Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$56M | -110.5% | -$58M | $-1.41 | - | - |
| 2024 | -$27M | +29.4% | -$30M | $-0.73 | - | - |
| 2023 | -$38M | -93.2% | -$35M | $-5.37 | - | - |
| 2022 | -$19M | -128.6% | -$18M | $-8.77 | - | - |
| 2021 | -$9M | -29.9% | -$8M | $-5.00 | - | - |
| 2020 | -$7M | -723.7% | -$6M | $-7.46 | - | - |
| 2019 | $1M | +105.5% | -$7M | $1.98 | - | - |
| 2018 | -$19M | -520.4% | -$5M | $-36.51 | - | - |
| 2017 | -$3M | +2.6% | -$4M | $-25.62 | - | - |
| 2016 | -$3M | +34.4% | -$4M | $-39.90 | - | - |
See SKYE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SKYE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SKYE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSKYE — Frequently Asked Questions
Quick answers to the most common questions about buying SKYE stock.
Is SKYE growing earnings?
SKYE EPS fell to $-1.41, with earnings declining -93.2%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-56M.
What are SKYE's profit margins?
Skye Bioscience, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are SKYE's earnings?
SKYE earnings data spans 2012-2025. The declining earnings trend is -93.2% YoY. Historical data enables comparison across business cycles.